Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Shares Outstanding (Weighted Average) (2024 - 2025)

Humacyte has reported Shares Outstanding (Weighted Average) over the past 2 years, most recently at $40.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $40.9 million for Q4 2025, up 190.75% from a year ago — trailing twelve months through Dec 2025 was $40.9 million (up 190.75% YoY), and the annual figure for FY2025 was $40.9 million, up 190.75%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $40.9 million at Humacyte, up from $9.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for HUMA hit a ceiling of $143.5 million in Q2 2025 and a floor of $5.6 million in Q3 2024.